Alpha Teknova, Inc. (NASDAQ:TKNO – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $8.75.
TKNO has been the topic of several analyst reports. Weiss Ratings downgraded shares of Alpha Teknova from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. BTIG Research raised shares of Alpha Teknova from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a research note on Tuesday, August 11th. Zacks Research upgraded Alpha Teknova to a “hold” rating in a report on Thursday, August 6th. Roth Capital began coverage on Alpha Teknova in a research note on Wednesday, August 5th. They issued a “buy” rating and a $7.00 price objective on the stock. Finally, Wall Street Zen upgraded Alpha Teknova from a “hold” rating to a “buy” rating in a report on Saturday, August 8th.
Check Out Our Latest Stock Report on TKNO
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in TKNO. Deutsche Bank AG bought a new stake in Alpha Teknova during the 2nd quarter valued at $62,000. Ieq Capital LLC acquired a new position in shares of Alpha Teknova in the 2nd quarter valued at $62,000. R Squared Ltd acquired a new position in shares of Alpha Teknova in the 1st quarter valued at $42,000. Susquehanna International Group LLP purchased a new position in Alpha Teknova in the 2nd quarter worth $115,000. Finally, Fielder Capital Group LLC purchased a new position in Alpha Teknova in the 2nd quarter worth $143,000. Hedge funds and other institutional investors own 13.81% of the company’s stock.
Alpha Teknova Price Performance
Shares of NASDAQ:TKNO opened at $7.81 on Friday. Alpha Teknova has a twelve month low of $1.91 and a twelve month high of $9.48. The firm’s 50 day moving average price is $7.73 and its 200-day moving average price is $4.98. The stock has a market capitalization of $491.25 million, a PE ratio of -26.93 and a beta of 0.96. The company has a quick ratio of 3.48, a current ratio of 4.49 and a debt-to-equity ratio of 0.21.
Alpha Teknova (NASDAQ:TKNO – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Alpha Teknova had a negative net margin of 34.76% and a negative return on equity of 24.41%. The business had revenue of $12.70 million during the quarter, compared to analyst estimates of $11.71 million. Equities research analysts expect that Alpha Teknova will post -0.26 EPS for the current year.
About Alpha Teknova
Alpha Teknova, Inc is a life sciences company that develops and manufactures critical reagents and other products used in biomedical research, biopharmaceutical development and advanced therapies. The company provides laboratory and production materials designed to support applications including cell and gene therapy, molecular diagnostics, next-generation sequencing, vaccine development and pharmaceutical manufacturing.
Its offerings include research-use-only and current Good Manufacturing Practice (cGMP) reagents, buffers, media and other custom-formulated solutions.
Featured Stories
- Five stocks we like better than Alpha Teknova
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
